Comparative Pharmacology
Head-to-head clinical analysis: FEXINIDAZOLE versus PENTAMIDINE ISETHIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXINIDAZOLE versus PENTAMIDINE ISETHIONATE.
FEXINIDAZOLE vs PENTAMIDINE ISETHIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
Pentamidine isethionate is a synthetic aromatic diamidine that interferes with protozoal DNA replication, transcription, and RNA processing. Its exact mechanism is unclear but may involve inhibition of dihydrofolate reductase, interference with polyamine synthesis, and binding to kinetoplast DNA.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
Treatment of Pneumocystis jirovecii pneumonia (PCP): 4 mg/kg IV once daily for 21 days. Chemoprophylaxis of PCP: 300 mg inhalation via nebulizer every 4 weeks, or 4 mg/kg IV every 2-4 weeks. Treatment of leishmaniasis: 2-4 mg/kg IM or IV once daily or every other day for 14-30 doses.
None Documented
None Documented
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is 18-24 hours in patients with normal renal function; prolongs to >48 hours in renal impairment, necessitating dose adjustment.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Renal excretion accounts for approximately 60-70% of elimination, primarily as unchanged drug. Biliary/fecal elimination constitutes 10-20%, with the remainder undergoing metabolic clearance.
Category C
Category A/B
Antiprotozoal
Antiprotozoal